Optimization of DNA immunization against human cytomegalovirus (Q43654256)

25 November 2017

Optimization of DNA immunization against human cytomegalovirus (English)

1 reference

25 November 2017

0 references

0 references

9

Plotkin SA

1 reference

25 November 2017

10

Gönczöl E

1 reference

25 November 2017

Endrész V

1

1 reference

25 November 2017

Burián K

2

1 reference

25 November 2017

Berencsi K

3

1 reference

25 November 2017

Gyulai Z

4

1 reference

25 November 2017

Kari L

5

1 reference

25 November 2017

Horton H

6

1 reference

25 November 2017

Virok D

7

1 reference

25 November 2017

Méric C

8

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

25 November 2017

1 reference

25 November 2017

19

1 reference

25 November 2017

28-29

1 reference

25 November 2017

3972-3980

1 reference

High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

DNA vaccination against persistent viral infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

1 reference

7 January 2021

Biological features of genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

DNA and RNA-based vaccines: principles, progress and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

DNA immunization confers protection against murine cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

An improved plasmid DNA expression vector for direct injection into skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

A rapid microneutralization assay for cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Evaluation of tick-borne encephalitis DNA vaccines in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Gene inoculation generates immune responses against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Interferons in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

Interferon-alpha for viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900116-5

7 January 2021

10.1016/S0264-410X(01)00116-5

Identifiers

DOI

1 reference

25 November 2017

1 reference